In the ongoing search for new cancer treatments, companies including Context Therapeutics are developing potential therapies focused on the novel oncology target Claudin 6.

BioCentury’s analysis of first-in-human studies at ASCO 2023

Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines 

Plus: Co-founded by Slamon, ADC play Torl debuts with $158M B round and updates from Lux, Wellington, Lilly, Novo and more   

Early data for BNT211 show German biotech’s progress in applying CAR T cells to solid tumors, finding an effective application for cancer vaccines

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

On deck for the mRNA play are data for BNT211 plus CARVac, which is expected to give the CAR T therapy an efficacy boost for solid tumors

DISEASE CATEGORY: Cancer
INDICATION: Liver cancer An antibody-drug conjugate targeting the tight junction protein CLDN6 could treat hepatocellular carcinoma (HCC). In patients, high tumor levels of

How BioNTech is choosing which technologies to apply to different cancer settings

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors